To explore the evidence and knowledge gaps in sentinel node biopsy (SNB) in prostate cancer through a consensus panel of experts.
Introduction
Nodal metastases occur in 3-42% of men with clinically localized prostate cancer and the presence of nodal metastases has a strong negative impact on survival [1, 2] . Nodal dissection is considered the optimum staging tool, but the therapeutic value of nodal dissection is not proven, and more extensive nodal dissection is associated with increased morbidity [3] . Sentinel node biopsy (SNB) uses the lymphatic drainage of intra-or peri-tumoural injected tracers to identify those lymph nodes most likely to contain metastases. After injection, the tracer, often radioactively labelled, can be visualized by scintigraphy and single-photon emission CT. Preoperative imaging and intra-operative detection can subsequently be used to resect the sentinel node (SN). In breast cancer, SNB has been shown to provide similar staging accuracy to that of nodal dissection, while reducing morbidity [4] . SN detection improved survival when compared with conservative management in patients with melanoma [5] .
Since 1999, >7000 prostate cancer cases treated with SN detection have been reported in the literature [6] [7] [8] ; however, the role of SN detection in prostate cancer is considered experimental and no level-1 evidence regarding its clinical value is available. This is probably because of the considerable heterogeneity and inconsistency of definitions, thresholds, types of tracer, descriptions of interventions and approaches, detection methods, and outcome selection, measurement and reporting in the literature [7] [8] [9] . Several recent studies have reported on the limited value of SNB. When applied without a complementary extended nodal dissection high false-negative rates were reported. Moreover, limiting nodal dissection to SNB may result in inadequate nodal metastases removal because, in many cases, metastases are present in non-SNs next to positive SNs [10] [11] [12] [13] .
The objective of the present study was to develop and issue consensus statements to standardize the most important elements of SNB, including patient selection, definition of an SN, descriptions of technique and approaches, tracer type and detection, and outcome measurement and reporting, in order to provide guidance for clinicians and researchers.
Methods

Consensus Process
The consensus building process was divided into two phases: (1) a two-round Delphi survey involving an international panel of healthcare professionals and researchers involved in the field of SNB for prostate cancer; and (2) a consensus group meeting involving a panel of experts and researchers.
We thereby followed early tested and reported protocols for consensus finding [14] [15] [16] [17] .
Delphi survey
A systematic review of the literature was performed in order to define and characterize the heterogeneity and inconsistency of all domains relating to SNB as reported in the literature. The objectives, methods and findings of the review are reported elsewhere [7] . Based on the review of the literature, differences among studies rendered comparison of data difficult. To obtain consensus on all the aspects of SN detection we divided the areas where heterogeneity was observed into nine different domains. The domains were organized as follows: (1) definition of SNs; (2) patient selection; (3) prophylactic antibiotic use; (4) technique or approach of performing SNB; (5) type of tracer and detection methods; (6) histological assessment of SNs; (7) reporting of SNB findings; (8) diagnostic accuracy outcome measures; and (9) clinical effectiveness outcome measures, including complications and oncological outcomes ( Table 1) . The review findings were summarized as a long list of domainspecific items or statements, which were collated into an online questionnaire [18] . The survey was prepared and cross-checked for consistency with the review findings by at least two individuals independently (H.v.d.P., E.W., T.L. and S.M.). An international panel of healthcare professionals and researchers including urologists, nuclear medicine specialists, trialists and methodologists involved in the field of SNB for prostate cancer were purposively sampled and invited by email to participate in the survey. Participants were identified through their authorship of studies on SNB and through the membership directory of the European Association of Urology; 50 participants were invited, of whom 43 completed the first survey round and 30 the second round. Two iterative rounds were conducted and, after each round, participants were provided with anonymized feedback regarding the mean ranking score for the whole group for each item. Participants 14  10  6  60  2  Patient selection  48  35  21  60  3  Prophylactic antibiotics  4  3  2  66  4  Tracer technology  46  55  26  47  5  Surgical intervention  29  25  17  68  6  Histology  2  ---7  Reporting  1  ---8  Diagnostic accuracy  4  4  3  75  9  Outcome  19  18  16  89  167  150  91 had the opportunity to add further items to the survey in round one for incorporation into the following round. Voting was conducted online anonymously. Consensus was defined as agreement by ≥70% of participants in the final round. After the final round, items reaching consensus were collated for review at the subsequent consensus group meeting, and items on which consensus had not been reached were brought forward for discussion and voting at the meeting.
Consensus group meeting
A two-day consensus group meeting was held to review items on which consensus had been reached, and to discuss and vote on items on which consensus had not been reached. Participants were urologists, nuclear medicine specialists, methodologists, trialists and a patient representative; these were invited by email and had participated in the Delphi survey rounds. The meeting was also attended by non-voting participants, consisting of urologists or methodologists with an interest in the field of SNB, and representatives of the sponsors. It was chaired by a non-voting member, Dr Steven MacLennan, Research Fellow, Academic Urology Unit, University of Aberdeen, UK. The survey was conducted as a series of statements, and participants were asked to vote based on their level of agreement, on a nine-point scale, ranging from strongly disagree (1) to strongly agree (9) (i.e. 1-3 disagree; 4-6 uncertain; 7-9 agree). Voting was undertaken anonymously online via Survey Monkey, which participants could only access during the meeting using their own personal computers based on a shared IP address. Consensus was achieved when the two following criteria were fulfilled: (1) median score of 7-9 (consensus agree) or 1-3 (consensus disagree); AND (2) no disagreement regarding the scoring. Disagreement was measured using the research and development project (RAND)/University of California, Los Angeles (UCLA) Appropriateness Method [19] ): and assumed when the interpercentile range (IPR; difference between the 30th and 70th percentiles) was larger than the interpercentile range adjusted for symmetry (IPRAS), which was calculated using the following formula: IPRAS = 2.35 + (asymmetry index 9 1.5), where the asymmetry index is the absolute difference between 5 and the central point of the IPR. The disagreement index (DI) was measured using the following formula: disagreement index = IPR/IPRAS; if DI <1.0, then there was no extreme variation regarding the scoring (i.e. consensus agreement or consensus disagreement).
Results
Delphi Survey
The systematic review confirmed significant heterogeneity and inconsistency in all nine domains relating to SNB and will be published separately [8] . After the review, 167 items across all domains were prioritized and incorporated into Survey Monkey as 42 questions (Table S1 ). A total of 30 participants (70%) completed both rounds of the survey. Forty additional items were proposed by participants in round one, and these were incorporated into round two.
Consensus Group Meeting
The consensus group meeting was held at the Karl Storz Training Centre, Berlin, Germany (February 25-26, 2016). A total of 23 participants attended, of whom 16 were voting members. The list of participants and voting status are summarized in Table 2 . After discussion of the survey results, a few items were re-phrased to achieve greater clarity and reduce ambiguity immediately before voting.
Final Consensus Statements
The items on which consensus was reached are summarized in Table 3 , organized by domains. The final consensus statements from the study and the results of the voting for each item are summarized in Table S1 .
Discussion
Principal Findings
The main purpose of the project was to establish consensus statements for SNB in prostate cancer in order to standardize all elements associated with the procedure and hence provide guidance for clinical practice and researchers. A previous systematic review confirmed significant heterogeneity and inconsistency in undertaking SNB, and identified items requiring consensus [7, 8] . Through a Delphi survey followed by a consensus group meeting, consensus was achieved on 35 The most appropriate tracer to detect an SN or lymph node landing site of the prostate is 99mTc-nanocolloid Agreement The most appropriate tracer to detect an SN or lymph node landing site of the prostate is Hybrid tracer (fluorescence and radioactive) Agreement In terms of suitability for an SN procedure, intermediate risk group is suitable Agreement The most appropriate tracer to detect an SN or lymph node landing site of the prostate is fluorescent ICG Agreement The most appropriate tracer to detect an SN or lymph node landing site of the prostate is Preoperatively perform SN mapping using hybrid tracer and radioactive signature; then Intra-operatively use fluorescence signature hybrid tracer, and if unsure perform gamma tracing of the radioactive signature of the hybrid tracer
Agreement
The optimal total volume of the tracer is 1-2 cc Agreement The optimal number of tracer injections in to the prostate is 4 Agreement The optimal location of tracer injection is into the peripheral zone of the prostate Agreement The optimal timing of post-injection imaging is 2 h after injeciton Agreement The optimal timing of post-injection imaging is dependent on the tracer and preoperative or intra-operative imaging Agreement The optimal time of injection prior to surgery is ICG immediately prior to surgery The best time of injection of a technetium tracer is less than 4-8 h prior to surgery. Agreement The best time of injection of a free ICG tracer is less than 0.5 h prior to surgery. Agreement The best time of injection of a bound ICG tracer is less than 2-4 h prior to surgery. Agreement The best time of injection of a free ICG tracer is less than 2-4 h prior to surgery. Disagreement The best time of injection of a free ICG tracer is less than 4-8 h prior to surgery. Disagreement The best time of injection of a free ICG tracer is less than 8-12 h prior to surgery. Disagreement The best time of injection of a free ICG tracer is less than 12 h prior to surgery. Disagreement The best time of injection of a bound ICG tracer is less than 0.5 h prior to surgery. Disagreement The optimal total volume of the tracer is ≤1 cc Disagreement The optimal total volume of the tracer is >2 cc Disagreement The optimal number of tracer injections in to the prostate is 2 Disagreement The best time of injection of a technetium tracer is less than 0.5 h prior to surgery. Disagreement The best time of injection of a technetium tracer is less than 1-2 h prior to surgery.
Disagreement 5. Surgical intervention
The best way to detect sentinel nodes intra-operatively is the NIR fluorescence imaging Agreement The best way to detect sentinel nodes intra-operatively is the gamma probe or NIR imaging Agreement The optimal gamma probe detection angle for intra-operative detection of SNs is 45 degrees Agreement The optimal gamma probe detection angle for intra-operative detection of SNs is 90 degrees Agreement In terms of additional lymph node dissection, an SN procedure for prostate cancer should be combined with an eLND in most situations but in selected cases lymph node dissection can be omitted
Agreement
The optimal number of SNs that should be detected during an SN procedure is 2-5 Agreement The optimal number of SNs that should be detected during an SN procedure is 2-5 per hemi-pelvic side Agreement The optimal number of SNs that should be detected during an SN procedure is patient-dependent (usually >2) Agreement The optimal number of lymph nodes that should be removed with a nodal dissection for prostate cancer, balancing toxicity and oncological accuracy is 16-20
In low-risk patients analysis of the SN(s) is enough. In intermediate-and high-risk patients, an eLND must be performed too Agreement The optimal number of lymph nodes that should be removed with a nodal dissection for prostate cancer, balancing toxicity and oncological accuracy is >25
Disagreement
Until not otherwise proven or other tumour-specific tracers are available, eLND is needed in all patients Disagreement In terms of additional lymph node dissection, an SN procedure for prostate cancer should always be combined with a limited lymph node dissection Disagreement In terms of additional lymph node dissection, an SN procedure for prostate cancer can always be performed without an additional lymph node dissection
In terms of additional lymph node dissection, an SN procedure for prostate cancer should always be combined with an eLND Disagreement The optimal number of SNs that should be detected during an SN procedure is >10 Disagreement The optimal number of lymph nodes that should be removed with a nodal dissection for prostate cancer, balancing toxicity and oncological accuracy is 11-15 Disagreement 6. Histology: no consensus voting needed 7. Reporting: no consensus voting needed 8. Diagnostic test accuracy In studies of diagnostic accuracy of the SN procedure using eLND as reference standard, the diagnostic test accuracy outcome should include number of positive nodes
Agreement
In studies of diagnostic accuracy of the SN procedure using eLND as reference standard, the diagnostic test accuracy outcome should include number of nodes outside the extended nodal dissection template
In studies of diagnostic accuracy of the SN procedure using eLND as reference standard, the diagnostic test accuracy outcome should include % of men with metastases limited to SNs
In studies of diagnostic accuracy of the SN procedure using eLND as reference standard, the diagnostic test accuracy outcome should include sensitivity Agreement In studies of diagnostic accuracy of the SN procedure using eLND as reference standard, the diagnostic test accuracy outcome should include specificity Agreement In studies of diagnostic accuracy of the SN procedure using eLND as reference standard, the diagnostic test accuracy outcome should include positive predictive value
In studies of diagnostic accuracy of the SN procedure using eLND as reference standard, the diagnostic test accuracy outcome should include negative predictive value
In studies of diagnostic accuracy of the SN procedure using eLND as reference standard, the diagnostic test accuracy outcome should include false-negative rate
In studies of diagnostic accuracy of the SN procedure using eLND as reference standard, the diagnostic test accuracy outcome should include false-positive rate
In SN dissection, false negatives are defined as SNs which are histologically negative for cancer whilst cancer is found in other lymph nodes according to an extended dissection template. An acceptable false-negative rate is >10-≤15%
Disagreement
In SN dissection, false-negatives are defined as SNs which are histologically negative for cancer whilst cancer is found in other lymph nodes according to an extended dissection template. An acceptable false-negative rate is >15 to ≤20%
In SN dissection, false-negatives are defined as SNs which are histologically negative for cancer whilst cancer is found in other lymph nodes according to an extended dissection template. An acceptable false-negative rate is >20% Disagreement 9. Outcome In studies of SN procedure for prostate cancer, the complication rate (measured by Clavien-Dindo grading) is an important non-oncological outcome to measure
Agreement
In studies of SN procedure for prostate cancer, operating time is an important non-oncological outcome to measure Agreement In studies of SN procedure for prostate cancer, transfusion rate is an important non-oncological outcome to measure Agreement In studies of SN procedure for prostate cancer, urinary incontinence is an important non-oncological outcome to measure Disagreement SN, sentinel node; eLND,extended lymph node dissection.
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Definition of sentinel node
Various definitions of SN were identified from the review of the literature [7] . During the consensus group meeting, voting on 11 definitions was performed (Table S1 ). Consensus 'agreement' was obtained on six of these definitions, with the strongest agreement reached for 'All nodes that appear first in each drainage basin as seen on early (15 min) lymphoscintigrams and/or single-photon emission CT imaging in new basins that were not yet seen on the early images' (Fig. 1 ). There was one consensus 'disagreement' for the definitions, for 'All fluorescent nodes'. This implies that the panel mainly agreed on the specificity of SN detection. The SNB can be used to identify those nodes that are most likely to, but do not necessarily exclusively, contain nodal metastases.
Patient selection
Consensus 'agreement' on 13 of 35 statements on patient selection was obtained, whereas consensus 'disagreement' was found for eight statements (Table S1 ). Unanimous agreement (i.e. median score of 9 and DI = 0) was obtained on two statements: 'In terms of suitability for a sentinel node procedure, the intermediate risk group is suitable' and 'In terms of suitability for a sentinel node procedure, high risk groups are suitable, but require additional extended lymphadenectomy'. The panel also achieved consensus regarding the fact that age, body mass index, prostate size, tumour location and size, previous TURP or prostatitis were not important criteria in selecting patients for SNB. No consensus was reached on SNB in low-risk cancer and BPH as exclusion criteria.
Sentinel node tracer and detection
Consensus agreement was obtained on 15 of 55 statements related to tracers, and consensus disagreement on 12 (Table S1 ). The panel members agreed on the use of the following tracers for SNB: '99m[technetium]Tc-nanocolloid', 'hybrid (99mTc/ ICG) tracer', and 'ICG' (indocyanine green). Agreement was obtained on the fact that '1-2 cc of tracer volume was deemed most suitable in four injections preferably in the peripheral zone of the prostate'. The panel agreed on the statement that 'the optimal timing of post-tracer-injection imaging is dependent on the chosen tracer'. The panel also agreed on the fact that 'intra-operative ICG imaging may replace 99mTc-gamma probe detection during surgery'.
The optimum time interval between tracer injection and surgery was '4-8 h' for 99mTc-based tracers, '<30 min' for free-ICG as tracer, and '2-4 h' for the bound-ICG tracer.
Consensus disagreement was obtained for intervals '>2 h' for free-ICG, and an interval '<30 min' for bound ICG.
The panel disagreed with the use of 'low (<1 cc)' and 'high (>2 cc)' tracer volume injections, and 'two injections'. Also the panel disagreed with the use of 'very small particle size (<80 nm)'.
Interestingly, no consensus could be obtained on the use of tracers such as albumin, tilmanocept, superparamagnetic ironoxide, or sulphur-containing tracers and on the 'optimal radioactive dose for the tracer (mBq)'.
Regarding the optimum route of tracer administration, consensus was reached in the Delphi survey for 'transrectal' route (86% of participants) and under 'transrectal ultrasound guidance' (86% of participants).
Interventions
Consensus 'agreement' was obtained on 10 of 22 statements on surgical intervention. The panel agreed that both 'gamma probe detection' and 'near infrared imaging' were useful for intra-operative SN imaging. There was agreement that the optimum number of SNs was 2-5 but was also patientdependent. The panel agreed that the optimum number of lymph nodes that should be removed with a nodal dissection for prostate cancer, balancing toxicity and oncological accuracy, is [16] [17] [18] [19] [20] . There was also agreement that in those cases where no SN was visualized, an eLND was indicated.
Histological assessment
The panel achieved consensus agreement on the optimum histological processing of the SNs, which was 'formalin-fixed paraffin-embedded with 400-lm sections', and that immunostaining should be applied to exclude micrometastases (Table S1 ).
Reporting of sentinel node biopsy findings
In the Delphi survey, consensus agreement was reached on 'anatomical location as the preferred reporting method of SN location' (76% of respondents; Table S1 ).
Antibiotic prophylaxis
Three statements on antibiotic prophylaxis for SNB were voted on by the consensus panel (Table S1 ). A single antibiotic dose was agreed on as the optimum antibiotic prophylaxis for the procedure.
Diagnostic accuracy outcome measures
The panel reached consensus agreement regarding the calculation of diagnostic test accuracy, in that all SNB studies should report on the following elements: sensitivity; specificity; negative predictive value; positive predictive value; false-negative rate; and false-positive rate. The consensus definition for false positives is 'patients with positive SN outside the eLND template with a negative eLND', and for false-negatives it is 'patients with nodal metastases in eLND but negative SN'. There was also consensus 'agreement' that sensitivity of SN detection is the most important diagnostic test accuracy element.
Whilst the false-positive definition is counter-intuitive, it is imperative to adhere to standardized criteria in calculating diagnostic accuracy, which must be based on the reference standard (i.e. eLND). This reflects the imperfect use of eLND as a reference standard.
Clinical effectiveness outcome measures
There was consensus agreement that the following outcome measures should be reported in any SNB study: number of positive nodes, number of SN outside eLND template, and number of patients with metastases to SN only (Table S1 ). There was also consensus agreement that an acceptable outcome for SNB was 'similar oncological outcome but reduced toxicity compared to eLND'.
Regarding non-oncological outcome measures, there was consensus agreement that the following measures were important: complication rate, operating time and transfusion rate. For complications, the panel reached consensus agreement regarding the aim that 'Clavien-Dindo [20] grade 1-2 complications should occur in less than 10% of cases', and that 'grade 3-5 complication should occur in 0-2% of cases'. The majority of respondents (86%) stated that adding SN detection to lymph node dissection in prostate cancer does not increase the risk of complications (Table S1 ).
Implications of Study Findings on Clinical Practice and Research
For researchers and trialists, the consensus statements provide guidance in terms of trial design, patient selection, interventions, and outcome measurement and reporting. By reducing heterogeneity and inconsistency across all the elements of SNB, the results of future studies can be compared more meaningfully. Future work should focus on prospectively assessing the diagnostic test accuracy of SNB based on eLND as the reference standard as well as oncological outcome. Given these uncertainties in the meantime, SNB should be considered experimental.
Strengths and Limitations
The strengths of the present study include the robust, transparent, standardized and reproducible methods used to achieve consensus. The study involved an international, large, purposively-sampled and diverse group of participants involved with SNB.
In terms of limitations, the majority of panel members had personal experience with SN detection, which may have introduced a bias. We anticipated that the panel composition would be helpful to assess criteria for future study design but acknowledge recent studies that found the SNB method not applicable for routine use [2, 12, 13] . Another potential limitation is the relatively high attrition rate in the Delphi survey (30.2%). To compensate for this, all items listed in the survey were reviewed at the consensus meeting. We adopted the RAND/ UCLA method for scoring the level of disagreement using the DI. A threshold DI value of 1 was arbitrarily selected [21] , but other methods can be considered. Some have suggested that the RAND/UCLA method's objective is not to reach consensus, but rather to evaluate where panel members agree [19] ; however, in the present study as the voting by panel members was preceded by the review of the data from the Delphi survey followed by a discussion on all statements, we believe that the voting results do indeed reflect consensus opinions.
Conclusions
The present report provides essential guidance for clinicians and researchers, and represents a major step forward in dealing with the issue of heterogeneity and inconsistency, affecting the conduct and reporting of studies on SNB.
Consensus was obtained on the definition of SNB. SNB can be used to identify those nodes that are most likely to, but do not necessarily exclusively, contain nodal metastases. SNB is an option for both intermediate-and high-risk prostate cancer.
The role of SNB in low-risk disease remains controversial. The members agreed on the timing and number of injections. Several tracers were found useful but no comparative data exist to recommend one over the other. For comparison the reference standard of SNB is eLND. In cases where SNB cannot be visualized, eLND is recommended.
Whilst SNB remains an attractive and promising staging intervention that may expand our options in managing men with localized prostate cancer, further work is required to determine its exact role and therapeutic value before it becomes established as a standard staging procedure.
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